Healthcare Providers

REQUEST A TRAINING KIT

For Your Patients

Fresenius Kabi provides complimentary injection training kits, which do not include the active ingredient. If you are a healthcare professional and would like to request an injection training kit, please fill out the form below.

Glucagon Emergency Training Kit
Each injection training kit contains:

  • 1 vial containing simulated glucagon powder
  • 1 needled syringe prefilled with distilled water for reconstitution
  • Pictured instructions* to assist in patient training

*Please see the Full Prescribing Information, including the Patient Information and Instructions for Use.

Glucagon Emergency Training Kit does not come with an injection pad.

This complimentary injection training kit is currently only available in the continental United States.

By submitting this form, you agree to the following:

I agree to the following terms and conditions: The Glucagon Emergency Training Kit is for instructional purposes only and is not intended for human or animal use. I acknowledge and agree that this will be used for instructional purposes only, and will not apply, inject, ingest, or otherwise use this Glucagon Emergency Training Kit on humans or animals. To use them otherwise is outside the scope and purpose for which they are intended and may be harmful to your health or the health of others.

By entering your email address, you are Opting In to receive emails from Fresenius Kabi. This will allow us to digitally communicate with you via emails which might contain newsletters, product information and updates. You may withdraw your censent at any time by clicking the Unsubscribe link in our emails.

Fresenius Kabi provides complimentary injection training kits, which do not include the active ingredient.

FOR TRAINING PURPOSES ONLY
NOT FOR HUMAN OR ANIMAL USE
DOES NOT CONTAIN DRUG PRODUCT

Important Safety Information


Indication and Usage
Glucagon for Injection is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.

Important Safety Information
Glucagon for Injection is contraindicated in patients with pheochromocytoma, insulinoma, or a known hypersensitivity to glucagon or any of the excipients.

Catecholamine Release in Patients with Pheochromocytoma: Glucagon for Injection is contraindicated in patients with pheochromocytoma because Glucagon for Injection may stimulate the release of catecholamines from the tumor.

Hypoglycemia in Patients with Insulinoma: In patients with insulinoma, administration may produce an initial increase in blood glucose; however, Glucagon for Injection may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously.

Hypersensitivity and Allergic Reactions: Allergic reactions have been reported and include generalized rash, and in some cases anaphylactic shock with breathing difficulties, and hypotension.

Lack of Efficacy in Patients with Decreased Hepatic Glycogen: Glucagon for Injection is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for Glucagon for Injection to be effective. Patients with these conditions should be treated with glucose.

Necrolytic Migratory Erythema (NME): a skin rash, has been reported postmarketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.

Most common adverse reactions (>5% or greater incidence): Injection site swelling, injection site erythema, vomiting, nausea, decreased blood pressure, asthenia, headache, dizziness, pallor, diarrhea, and somnolence.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Beta-blockers: Patients taking beta-blockers may have a transient increase in pulse and blood pressure.

Indomethacin: In patients taking indomethacin Glucagon for Injection may lose its ability to raise glucose or may produce hypoglycemia.

Warfarin: Glucagon for Injection may increase the anticoagulant effect of warfarin.

This Important Safety Information does not include all the information needed to use Glucagon for Injection safely and effectively. Please see the full prescribing information for Glucagon for Injection and Patient Information. The full prescribing information is also available at www.fresenius-kabi.com/us.

© Fresenius Kabi USA, LLC 2025

Privacy Notice    Terms of Use    Data Privacy Contact   Cookie Notice
Consumer Health Data Privacy Notice Supplement
Limit The Use of My Sensitive Personal Information